# Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

> **NCT00395460** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 147 (actual)

## Conditions studied

- Central Nervous System Diseases

## Interventions

- **DRUG:** Gadobutrol (Gadavist, Gadovist, BAY86-4875)
- **DRUG:** Magnevist

## Key facts

- **NCT ID:** NCT00395460
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395460, "Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00395460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*